

Tysabri Order Form (natalizumab)

FAX TO: 972.499.9210

PATIENT INFORMATION					
Patient Name:	Allergies:				· ·
<icd 10="" code="" required=""></icd>	DIAGNOSIS & CLI	NICAL INFORMATIC)N		
ICD 10 Code G35 Multiple Sclerosis Other:	Product information suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of therapy.				
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS</u> : Include anti-JCV antibodies test results within last 6 months (Patients who are anti-JCV antibody positive will require documentation from prescriber that risks/benefits have been discussed.)					
	PRESC	CRIPTION			
Pre-Medications Acetaminophen: 650 mg PO Cetirizine: 10 mg PO Diphenhydramine: 25 mg PO					
TYSABRI (natalizumab)					
Loading Dose IV: Infuse 300 mg in 100 ml of 0.9% Sodium Chloride over at least 60 minutes every 4 weeks (no less than 28 days) for one year					
Is the patient on any other disease modifying therapy? Yes No If yes, please note therapy and last dose:					
Post Treatment Observations: The patient is observed for 1 hour following the first 12 infusions and 15 minutes following the 13th and subsequent infusions.					
Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.					
Comments:					
PRESCRIBER INFORMATION					
Prescriber Name:	Signature:				
Date: NPI #:		_ Specialty:			
Supervising Physician:					_ (If Applicable)
Address:	City:		State: _	Zip:	
Contact Name:	Phone:	Fax:	Email:		